<DOC>
	<DOCNO>NCT01375972</DOCNO>
	<brief_summary>To select good agent S-1 gemcitabine combination cisplatin conventional chemotherapy platform future development advance Biliary Tract Adenocarcinoma ( BTA ) , investigator conduct randomize phase II trial S-1 cisplatin ( SP ) versus gemcitabine cisplatin ( GP ) first line therapy advance BTA .</brief_summary>
	<brief_title>Trial S-1 Plus Cisplatin ( SP ) Versus Gemcitabine Plus Cisplatin ( GP ) Advanced Biliary Tract Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Pathologically proven biliary adenocarinoma 2 . Age &gt; 18 3 . Evaluable disease 4 . ECOG performance status 2 well 5 . No prior exposure chemotherapy , adjuvant chemotherapy ( chemoradiotherapy ) complete 6 moth study enrollment allow 6 . Adequate bone marrow function A. WBCs &gt; 4,000/µL , absolute neutrophil count [ ANC ] &gt; 1,500/µL B. Hemoglobin &gt; 9.0 g/dL C. Platelets &gt; 100,000/µL 7 . Adequate kidney function ( creatinine &lt; 1.5 mg/dL ) 8 . Adequate liver function ( bilirubin &lt; 1.5 mg/dL [ &lt; 2.5 mg/dL obstructive jaundice adequately decompress bile duct obstruction ] , transaminases level &lt; 3 time upper normal limit , serum albumin &gt; 2.5 mg/dL ) 9 . No serious medical psychological condition would preclude study treatment 10 . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure 1 . Other tumor type adenocarcinoma 2 . Evidence GI bleeding GI obstruction 3 . Presence history CNS metastasis 4 . Pregnancy breastfeed 5 . Other serious illness medical condition 6 . Axial skeletal radiotherapy within 6 month 7 . Neuropathy grade 2 worse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>biliary cancer</keyword>
	<keyword>systemic chemotherapy</keyword>
	<keyword>S-1</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>cisplatin</keyword>
</DOC>